This inventor holds 1 USPTO granted patent. Top assignee: Vela Acquisition Corporation. Active years: 2009.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2009
Title: Yungen Xu: Innovator in Benzodiazepine Conversion Processes
Introduction
Yungen Xu is a notable inventor based in Baltimore, MD (US). He has made significant contributions to the field of chemistry, particularly in the area of benzodiazepine compounds. His innovative work has led to the development of a unique patent that addresses the conversion processes of these important molecules.
Latest Patents
Yungen Xu holds a patent for a conversion process for 2,3-benzodiazepine enantiomers. This patent describes methods for the racemization of an enantiomer of a 2,3-benzodiazepine molecule into the corresponding racemic mixture under either basic or acidic conditions. Furthermore, the invention relates to the conversion of an enantiomer of tofisopam or its metabolites to the corresponding opposite enantiomer. This work is crucial for advancing the understanding and application of benzodiazepine compounds in various medical and pharmaceutical contexts.
Career Highlights
Yungen Xu is currently associated with Vela Acquisition Corporation, where he continues to apply his expertise in chemical processes. His work at the company reflects his commitment to innovation and the advancement of scientific knowledge. With one patent to his name, he has established himself as a valuable contributor to the field.
Collaborations
Yungen Xu collaborates with talented individuals such as Yong Victoria Wei and Naidaong Ye. These partnerships enhance the research and development efforts within his field, fostering an environment of creativity and innovation.
Conclusion
Yungen Xu's contributions to the field of chemistry, particularly through his patent on benzodiazepine conversion processes, highlight his role as an important inventor. His work not only advances scientific understanding but also has practical implications in the pharmaceutical industry.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile